---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 10-QSB

(Mark One)

[X]Quarterly Report Under Section 13 Or 15(d) Of The
Securities Exchange Act Of 1934

For the quarterly period ended April 30, 2007

[ ] Transition Report Under Section 13 Or 15(d) Of The Exchange
Act

For the transition period from ________ to ________

COMMISSION FILE NUMBER000-51573

VITAVEA INC.(Exact name of
small business issuer as specified in its charter)

|NEVADA                                           | 20-0848675                       
|------------------------------------------------ | ---------------------------------
|(State or other jurisdiction of incorporation or | (IRS Employer Identification No.)
|organization)                                    |                                  

1323 Lincoln Street, #204 Bellingham, WA 98229(Address of principal executive offices)

(360) 483-8248(Issuer's telephone number)

Not Applicable(Former name, former address
and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be
  filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
  for such shorter period that the registrant was required to file such reports),
  and (2) has been subject to such filing requirements for the past 90 days.Yes [ X ]No [ ]

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]

State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date: As of June 19,
2007, the Issuer had 110,973,358 Shares of Common Stock outstanding.

Transitional Small Business Disclosure Format (check one): Yes [
] No [X]

---

PART I - FINANCIAL INFORMATION

|ITEM 1. | FINANCIAL STATEMENTS.
|------- | ---------------------

2

---

|VITAVEA INC.                        
|------------------------------------
|(formerly GA Computer Sciences Inc.)
|(A Development Stage Company)       
|                                    
|                                    
|CONSOLIDATED FINANCIAL STATEMENTS   
|(Expressed in U.S. Dollars)         
|                                    
|April 30, 2007                      
|(Unaudited)                         

---

|VITAVEA INC.                        
|------------------------------------
|(formerly GA Computer Sciences Inc.)
|(A Development Stage Company)       
|CONSOLIDATED BALANCE SHEET          
|(Expressed in U.S. Dollars)         
|(Unaudited)                         

|                                                                        |   | April 30,  |  
|----------------------------------------------------------------------- | - | ---------- | -
|                                                                        |   | 2007       |  
|                                                                        |   |            |  
|ASSETS                                                                  |   |            |  
|                                                                        |   |            |  
|Current Assets                                                          |   |            |  
|Cash and cash equivalents                                               | $ | 139,332    |  
|Other receivables                                                       |   | 320,203    |  
|Inventory                                                               |   | 513,713    |  
|Prepaid expenses                                                        |   | 6,795      |  
|Deferred acquisition costs (Note 3)                                     |   | -          |  
|Deferred tax asset, less valuation allowance
      of $1,324,541        |   | -          |  
|Total Current Assets                                                    |   | 980,043    |  
|                                                                        |   |            |  
|Equipment (Note 4)                                                      |   | 1,791      |  
|Patent (Note 4)                                                         |   | 25,592     |  
|                                                                        |   |            |  
|Total Assets                                                            | $ | 1,007,426  |  
|                                                                        |   |            |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                    |   |            |  
|                                                                        |   |            |  
|Current Liabilities                                                     |   |            |  
|Accounts payable and accrued liabilities                                | $ | 365,466    |  
|Accounts payable and accrued liabilities
      related parties (Note 6) |   | 7,780      |  
|Loans payable current (Note 5)                                         |   | 262,258    |  
|Loans
      payable –current –related parties (Note 6)                  |   | 20,472     |  
|                                                                        |   |            |  
|Total Current Liabilities                                               |   | 655,976    |  
|                                                                        |   |            |  
|                                                                        |   |            |  
|Commitments (Note 3, 9)                                                 |   |            |  
|                                                                        |   |            |  
|Stockholders Equity                                                    |   |            |  
|Common stock (Note 7)                                                   |   |            |  
|Authorized                                                              |   |            |  
|750,000,000 common shares, par value $0.001                             |   |            |  
|Issued and outstanding                                                  |   |            |  
|110,973,358                                                             |   | 110,973    |  
|Additional paid-in capital                                              |   | 4,904,022  |  
|Accumulated other comprehensive loss:                                   |   |            |  
|Foreign currency cumulative
      translation adjustment                |   | (145,158   | )
|Deficit
      accumulated during the development stage                  |   | (4,518,387 | )
|                                                                        |   |            |  
|Total Stockholders
      Equity                                        |   | 351,450    |  
|                                                                        |   |            |  
|Total Liabilities
      and Stockholders Equity                        | $ | 1,007,426  |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-2

---

|VITAVEA INC.                                                      
|------------------------------------------------------------------
|(formerly GA Computer Sciences Inc.)                              
|(A Development Stage Company)                                     
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
      LOSS
|(Expressed in U.S. Dollars)                                       
|(Unaudited)                                                       

|                                              |   | Cumulative       |       |   |             |       |   |            |       |   |             |       |   |            |  
|--------------------------------------------- | - | ---------------- | ----- | - | ----------- | ----- | - | ---------- | ----- | - | ----------- | ----- | - | ---------- | -
|                                              |   | Amounts          |       |   | Six         |       |   | Six        |       |   | Three       |       |   | Three      |  
|                                              |   | From Inception   |       |   | Months      |       |   | Months     |       |   | Months      |       |   | Months     |  
|                                              |   | (March 31, 2004) |       |   | Ended       |       |   | Ended      |       |   | Ended       |       |   | Ended      |  
|                                              |   | to April 30,     |       |   | April 30,   |       |   | March 31,  |       |   | April 30,   |       |   | March 31,  |  
|                                              |   | 2007             |       |   | 2007        |       |   | 2006       |       |   | 2007        |       |   | 2006       |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|REVENUE                                       |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Sales                                         | $ | 29,944           |       | $ | 15,903      |       | $ | 798        |       | $ | 2,011       |       | $ | 225        |  
|Cost of goods sold                            |   | (104,498         | )     |   | (1,564      | )     |   | (19,341    | )     |   | (277        | )     |   | (277       | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Gross margin                                  |   | (74,554          | )     |   | 14,339      |       |   | (18,543    | )     |   | 1,734       |       |   | (52        | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|EXPENSES                                      |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Amortization                                  |   | 7,283            |       |   | 2,588       |       |   | 2,767      |       |   | 1,306       |       |   | 253        |  
|Professional fees                             |   | 555,500          |       |   | 290,795     |       |   | 29,709     |       |   | 180,912     |       |   | 1,956      |  
|Management fees                               |   | 37,861           |       |   | 13,886      |       |   | 7,473      |       |   | 6,981       |       |   | 3,738      |  
|Marketing expenses                            |   | 2,561,548        |       |   | 667,656     |       |   | 1,158,279  |       |   | (98,690     | )     |   | 830,668    |  
|Other operating expenses                      |   | 885,994          |       |   | 376,948     |       |   | 191,491    |       |   | 163,215     |       |   | 21,538     |  
|Foreign currency gain                         |   | (104,654         | )     |   | (104,654    | )     |   | -          |       |   | (126,472    | )     |   | -          |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Total expenses                                |   | 3,943,532        |       |   | 1,247,219   |       |   | 1,389,719  |       |   | 127,252     |       |   | 858,153    |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|LOSS BEFORE OTHER ITEMS,                      |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|AND INCOME TAXES                              |   | (4,018,086       | )     |   | (1,232,880  | )     |   | (1,408,262 | )     |   | (125,518    | )     |   | (858,205   | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Interest income                               |   | 32,147           |       |   | -           |       |   | 29,844     |       |   | -           |       |   | 15,698     |  
|Interest expense                              |   | (44,758          | )     |   | (2,778      | )     |   | (18,798    | )     |   | (1,463      | )     |   | -          |  
|Other income                                  |   | 2,315            |       |   | -           |       |   | -          |       |   | -           |       |   | -          |  
|Gain on settlement
      of debt              |   | 770,382          |       |   | -           |       |   | -          |       |   | -           |       |   | -          |  
|Writedown of acquisition costs                |   | (1,260,381       | )     |   | (1,260,381  | )     |   | -          |       |   | (1,260,381  | )     |   | -          |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|LOSS BEFORE INCOME TAXES                      |   | (4,518,381       | )     |   | (2,496,039  | )     |   | (1,397,216 | )     |   | (1,387,362  | )     |   | (842,507   | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Provision for income taxes                    |   | 6                |       |   | -           |       |   | 6          |       |   | -           |       |   | -          |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|NET LOSS                                      |   | (4,518,387       | )     |   | (2,496,039  | )     |   | (1,397,222 | )     |   | (1,387,362  | )     |   | (842,507   | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|OTHER COMPREHENSIVE LOSS                      |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|Foreign currency translation
      adjustment |   | (145,158         | )     |   | (96,259     | )     |   | 47,310     |       |   | 86,847      |       |   | 13,031     |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|COMPREHENSIVE LOSS                            | $ | (4,663,545       | )     | $ | (2,592,298  | )     | $ | (1,349,912 | )     | $ | (1,300,515  | )     | $ | (829,476   | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|BASIC
      AND DILUTED NET LOSS PER SHARE    |   | $                | (0.02 | ) | $           | (0.02 | ) | $          | (0.01 | ) | $           | (0.01 | )
|                                              |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|WEIGHTED AVERAGE NUMBER OF                    |   |                  |       |   |             |       |   |            |       |   |             |       |   |            |  
|COMMON SHARES OUTSTANDING                     |   |                  |       |   | 107,643,093 |       |   | 75,875,000 |       |   | 110,693,499 |       |   | 75,875,000 |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-3

---

|VITAVEA INC.                         
|-------------------------------------
|(formerly GA Computer Sciences Inc.) 
|(A Development Stage Company)        
|CONSOLIDATED STATEMENTS OF CASH FLOWS
|(Expressed in U.S. Dollars)          
|(Unaudited)                          

|                                                                                        |   | Cumulative       |   |   |            |   |   |            |  
|--------------------------------------------------------------------------------------- | - | ---------------- | - | - | ---------- | - | - | ---------- | -
|                                                                                        |   | Amounts          |   |   | Six        |   |   | Six        |  
|                                                                                        |   | From Inception   |   |   | Months     |   |   | Months     |  
|                                                                                        |   | (March 31, 2004) |   |   | Ended      |   |   | Ended      |  
|                                                                                        |   | to April 30,     |   |   | April 30,  |   |   | March 31,  |  
|                                                                                        |   | 2007             |   |   | 2007       |   |   | 2006       |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|CASH FLOWS FROM OPERATING ACTIVITIES                                                    |   |                  |   |   |            |   |   |            |  
|Net loss for the period                                                                 | $ | (5,288,763       | ) | $ | (2,496,039 | ) | $ | (1,397,222 | )
|Adjustments to reconcile net income to cash
      used in development stage activities: |   |                  |   |   |            |   |   |            |  
|Amortization                                                                            |   | 7,283            |   |   | 2,588      |   |   | 2,784      |  
|Gain on settlement of debt                                                              |   | 770,382          |   |   | -          |   |   | -          |  
|Writedown of acquisition costs                                                          |   | 1,219,616        |   |   | 1,219,616  |   |   | -          |  
|Additional paid-in capital                                                              |   | 1,240,459        |   |   | -          |   |   | -          |  
|Impairment loss on inventories                                                          |   | 96,225           |   |   | -          |   |   | -          |  
|Change in operating assets and liabilities                                              |   |                  |   |   |            |   |   |            |  
|Increase in other receivables                                                           |   | (283,513         | ) |   | (206,828   | ) |   | (129,829   | )
|Increase in inventory                                                                   |   | (494,556         | ) |   | (494,556   | ) |   | -          |  
|Increase in prepaid expenses                                                            |   | (6,197           | ) |   | -          |   |   | (93        | )
|Increase in assets not allocated to investing
      or financing activities             |   | (119,664         | ) |   | -          |   |   | -          |  
|Increase (decrease) in accounts payable
      and accrued liabilities                   |   | 283,440          |   |   | (4,478     | ) |   | 628,958    |  
|Increase
      in accounts payable and accrued liabilities – related parties            |   | 7,175            |   |   | 7,175      |   |   | -          |  
|Increase
      in accrued interest payable                                              |   | 21,576           |   |   | 2,778      |   |   | 18,092     |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|Net
      cash used in operating activities                                             |   | (2,546,537       | ) |   | (1,969,744 | ) |   | (877,310   | )
|                                                                                        |   |                  |   |   |            |   |   |            |  
|CASH FLOWS FROM INVESTING ACTIVITIES                                                    |   |                  |   |   |            |   |   |            |  
|Acquisition of equipment                                                                |   | (3,079           | ) |   | -          |   |   | (3,143     | )
|Acquisition of patent                                                                   |   | (29,655          | ) |   | -          |   |   | (29,952    | )
|Acquisition
      of MEBA & Baur deferred                                              |   | (1,219,616       | ) |   | (394,177   | ) |   | -          |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|Net
      cash used in investing activities                                             |   | (1,252,350       | ) |   | (394,177   | ) |   | (33,095    | )
|                                                                                        |   |                  |   |   |            |   |   |            |  
|CASH FLOWS FROM FINANCING ACTIVITIES                                                    |   |                  |   |   |            |   |   |            |  
|Cash acquired from Vitavea Inc.                                                         |   | 39,982           |   |   | 39,982     |   |   | -          |  
|Issuance of capital stock for cash                                                      |   | 2,433,909        |   |   | 2,365,559  |   |   | -          |  
|Proceeds from loan receivable                                                           |   | -                |   |   |            |   |   | 71,645     |  
|Proceeds from loans payable                                                             |   | 1,575,493        |   |   | 174,752    |   |   | -          |  
|Proceeds
      from loans payable –related parties                                      |   | 18,878           |   |   | 2,628      |   |   | 1,115,411  |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|Net
      cash provided by financing activities                                         |   | 4,068,262        |   |   | 2,582,921  |   |   | 1,187,056  |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|EFFECT OF FOREIGN CURRENCY TRANSLATION ON                                               |   |                  |   |   |            |   |   |            |  
|CASH AND CASH EQUIVALENTS
      DURING THE PERIOD                                       |   | (130,043         | ) |   | (81,137    | ) |   | 56,988     |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|NET INCREASE IN CASH                                                                    |   | 139,332          |   |   | 137,863    |   |   | 333,639    |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|CASH AND CASH EQUIVALENTS,
      BEGINNING OF PERIOD                                    |   | -                |   |   | 1,469      |   |   | 479,436    |  
|                                                                                        |   |                  |   |   |            |   |   |            |  
|CASH AND CASH EQUIVALENTS,
      END OF PERIOD                                          | $ | 139,332          |   | $ | 139,332    |   | $ | 813,075    |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-4

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   

|1. | HISTORY AND ORGANIZATION OF THE COMPANY
|-- | ---------------------------------------

Vitavea Inc. (formerly GA Computer Sciences
  Inc.) (the Company) was incorporated on March 10, 2004, under the
  Laws of the State of Nevada and was engaged in the business of producing, marketing
  and selling software created by Open Office in pre-packaged, shrink-wrapped
  standard compact disk jewel cases via the internet through the Companys
  website. Effective November 13, 2006, the Company acquired 100% of the issued
  and outstanding shares of Vitavea AG (Vitavea), a company engaged
  in the business of manufacturing, marketing and distributing nutritional supplements.
  The Company has abandoned its software business in order to focus its resources
  on the development of Vitaveas nutritional supplement business. The Company
  is considered to be a development stage company, as it has not generated significant
  revenues from operations.

Effective November 13, 2006, the Company
  acquired 100% of the issued and outstanding shares of Vitavea from WKB Beteiligungsgesellschaft
  mbH (WKB) and Crystalwood Holdings Inc. (Crystalwood)
  in exchange for Euro 300,000 and an aggregate of 34,350,000 shares of the Companys
  common stock. In addition, Peter Hoyle and Lina Zhou transferred an aggregate
  of 40,650,000 shares of the Companys common stock already issued and outstanding
  prior to the transaction to WKB in exchange for $10,000. Completion of the acquisition
  resulted in the former shareholders of Vitavea holding the majority of the Companys
  issued and outstanding common stock. As a result, the transaction was accounted
  for as a recapitalization of Vitavea.

The unaudited consolidated financial
  statements of the Company prior to November 13, 2006 are those of Vitavea. The
  Companys date of incorporation is considered to be March 31, 2004, the
  date of inception of Vitavea. Effective November 27, 2006, the Company changed
  its name from GA Computer Sciences Inc. to Vitavea Inc.

Effective March 31, 2006, Vitavea changed
  its year-end from December 31 to October 31 to correspond with the Companys
  year-end. Comparative financial information for the six and three months ended
  March 31, 2006 has been included in these unaudited financial statements.

These unaudited financial statements
  have been prepared in conformity with generally accepted accounting principles
  in the United States of America for interim financial information. The accompanying
  consolidated financial statements do not include all information and footnote
  disclosures required for an annual set of financial statements prepared under
  United States of America generally accepted accounting principles. In the opinion
  of management, all adjustments (consisting solely of normal recurring accruals)
  considered necessary for a fair presentation of financial position, results
  of operations and cash flows as at April 30, 2007 and for all periods presented,
  have been included. Interim results for the period ended April 30, 2007 are
  not necessarily indicative of the results that may be expected for the fiscal
  year as a whole.

F-5

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|2. | GOING CONCERN
|-- | -------------

These consolidated financial statements
  have been prepared with the on-going assumption that the Company will be able
  to realize its assets and discharge its liabilities in the normal course of
  business. However, certain conditions noted below raise substantial doubt about
  the Companys ability to continue as a going concern. These financial statements
  do not include any adjustments to the amounts and classifications of assets
  and liabilities that might be necessary should the Company be unable to continue
  as a going concern.

The operations of the Company have primarily
  been funded by the sale of common stock and loans received. Continued operations
  of the Company are dependent on the Companys ability to complete equity
  financings or generate profitable operations in the future. Managements
  plan in this regard is to secure additional funds through future equity financings.
  Such financings may not be available or may not be available on reasonable terms
  to the Company.

|3. | SIGNIFICANT ACCOUNTING POLICIES
|-- | -------------------------------

The financial statements of the Company
  have been prepared in conformity with generally accepted accounting principles
  in the United States of America and are stated in U.S. dollars. The significant
  accounting policies adopted by the Company are as follows:

(a) Use of estimates

The preparation of financial statements
  in conformity with generally accepted accounting principles in the United States
  requires management to make estimates and assumptions that affect the reported
  amount of assets and liabilities and the disclosure of contingent assets and
  liabilities at the date of the financial statements and the reported amount
  of revenues and expenses during the reporting period. Actual results could differ
  from these estimates.

(b) Foreign currency translation

The functional currency of the Company
  is the U.S. dollar. The Companys subsidiary, Vitavea AG, uses the Euro
  as its functional currency. Accordingly, monetary assets and liabilities denominated
  in a foreign currency are translated at the exchange rate in effect at the balance
  sheet date while non-monetary assets and liabilities are translated at historical
  rates. Revenue and expense items denominated in a foreign currency are translated
  at exchange rates prevailing when such items are recognized in the statement
  of operations. Exchange gains and losses arising on translation of foreign currency
  items are included in the statement of operations.

The Company follows the current rate
  method of translation with respect to its foreign subsidiary. Accordingly, assets
  and liabilities are translated into U.S. dollars at the period-end exchange
  rates while revenue and expenses are translated at the average exchange rates
  during the period. Related exchange gains and losses are included in a separate
  component of stockholders equity as accumulated other comprehensive income.

F-6

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)
|-- | -------------------------------------------

(c) Cash and cash equivalents

The Company considers cash held at banks
  and all highly liquid investments with original maturities of three months or
  less to be cash and cash equivalents.

(d) Inventory

Inventory is valued at the lower of cost
  and net realizable value. Cost is determined on a first-in-first-out basis.
  Inventories consist of nutritional supplements and are all finished goods.

(e) Prepaid expenses

Prepaid expenses consist primarily of
  a refundable vehicle lease deposit.

(f) Other receivables

Other receivables consist primarily of
  Value Added Tax in Germany.

(g) Equipment

Equipment is recorded at cost and consists
  of computer equipment. Depreciation is calculated using the straight-line method
  over the useful lives of the assets. Maintenance and repairs are expensed as
  incurred while betterments or renewals are capitalized. Computer equipment is
  amortized over the estimated useful life of three years.

(h) Patents

Patents are recorded at cost. Capitalized
  amounts relate solely to the acquisition of one patent. Depreciation is calculated
  using the straight-line method over the useful life of the patent of eight years.

(i) Goodwill and intangible assets

The Company has adopted Statement of
  Financial Accounting Standards (SFAS) 142, Goodwill and
  Intangible Assets, which requires that costs of internally developing,
  maintaining or restoring intangible assets that are not specifically identifiable,
  that have indeterminate lives, or that are inherent in a continuing business
  and related to an entity as a whole, be recognized as an expense when incurred.
  Goodwill and intangible assets acquired for fair value having definite lives
  are amortized over their useful life.

F-7

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)
|-- | -------------------------------------------

(j) Accounting for the impairment
  of long-lived assets and long-lived assets to be disposed of

The Company reviews all long-lived assets
  for impairment whenever events or changes in circumstances indicate that the
  carrying amount of an asset may not be recoverable. Recoverability of assets
  to be held and used is measured by a comparison of the carrying amount of an
  asset to future net cash flows expected to be generated by the asset. If such
  assets are considered to be impaired, the impairment recognized is measured
  by the amount by which the carrying amount of the assets exceeds the fair value
  of the assets. Assets to be disposed of are reported at the lower of the carrying
  amount or fair value less costs to sell.

(k) Revenue recognition

The Company recognizes product revenue
  when persuasive evidence of an arrangement exists, delivery has occurred, the
  sales price is fixed or determinable and collectibility is reasonably assured.
  Revenue from products is recognized when title passes to the customer and all
  revenue recognition criteria specified above is met.

(l) Income taxes

A deferred tax asset or liability is
  recorded for all temporary differences between financial and tax reporting and
  net operating loss carryforwards. Deferred tax expenses (benefit) result from
  the net change during the period of deferred tax assets and liabilities.

Deferred tax assets are reduced by a
  valuation allowance when, in the opinion of management, it is more likely than
  not that some portion or all of the deferred tax assets will not be realized.
  Deferred tax assets and liabilities are adjusted for the effects of changes
  in tax laws and rates on the date of enactment.

(m) Fair value of financial instruments

The Company's financial instruments consist
  of cash and cash equivalents, other receivables, accounts payable and accrued
  liabilities and loans payable. Unless otherwise noted, it is management's opinion
  that the Company is not exposed to significant interest, currency or credit
  risks arising from these financial instruments. The fair value of these financial
  instruments approximates their carrying values, unless otherwise noted.

(n) Stock-based compensation

The Company accounts for stock-based
  compensation issued to employees in accordance with the provisions of SFAS 123R,
  Share-Based Payment.which superseded Accounting Principles
  Board (APB) Opinion 25, Accounting for Stock Issued to
  Employees.

F-8

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)
|-- | -------------------------------------------

(n) Stock-based compensation (continued)

The Company accounts for stock-based
  compensation issued to non-employees in accordance with the provisions of SFAS
  123, Accounting for Stock-Based Compensation, and the consensus
  in Emerging Issues Task Force (EITF) No. 96-18, Accounting
  for Equity Instruments that are Issued to Other Than Employees for Acquiring
  or in Conjunction with Selling, Goods or Services.

As of April 30, 2007, there have been
  no stock options granted.

(o) Net loss per share

Basic net loss per share is computed
  by dividing the net loss for the period by the weighted average number of shares
  of common stock outstanding during the period. Diluted earnings per share takes
  into consideration shares of common stock outstanding (computed under basic
  earnings per share) and potentially dilutive shares of common stock. As of April
  30, 2007, there were no potentially dilutive securities outstanding.

(p) Comprehensive income (loss)

The Company has adopted SFAS 130, Reporting
  of Comprehensive Income, which establishes guidelines for the reporting
  and display of comprehensive income (loss) and its components in financial statements.
  Comprehensive income (loss) includes foreign currency translation adjustments.

(q) Development stage

The Company is a development stage company
  as defined in SFAS 7, Accounting and Reporting by Development Stage
  Enterprises,as it is devoting substantially all of its efforts to
  establish a new business and planned principal operations have not yet commenced.

(r) Concentration of credit risk

Cash and cash equivalents is the only
  financial instrument that potentially subjects the Company to concentration
  of credit risk. The Company maintains cash in bank accounts that, at times,
  may exceed federally insured limits. The Company has not experienced any losses
  in such accounts and believes it is not exposed to any significant risks on
  its cash in bank accounts.

F-9

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)
|-- | -------------------------------------------

(s) Recent accounting pronouncements

In July 2006, the Financial Accounting
  Standards Board (FASB) issued FASB Interpretation No. (FIN)
  48, Accounting for Uncertainty in Income Taxes. FIN 48 clarifies
  the accounting and reporting for uncertainties in income tax law. FIN 48 prescribes
  a comprehensive model for the financial statement recognition, measurement,
  presentation, and disclosure of uncertain tax positions taken or expected to
  be taken in income tax returns. FIN 48 is effective for fiscal years beginning
  after December 15, 2006.

In September 2006, the SEC issued Staff
  Accounting Bulletin (SAB) No. 108, Considering the Effects
  of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial
  Statements. SAB No. 108 provides guidance on how prior year misstatements
  should be taken into consideration when quantifying misstatements in current
  year financial statements for purposes of determining whether the current years
  financial statements are materially misstated. SAB No. 108 is effective for
  fiscal years ending on or after November 15, 2006.

In September 2006, the FASB issued SFAS
  No. 157, Fair Value Measurements.SFAS No. 157 establishes
  a framework for measuring the fair value of assets and liabilities. This framework
  is intended to provide increased consistency in how fair value determinations
  are made under various existing accounting standards which permit, or in some
  cases require, estimates of fair market value. SFAS No. 157 is effective for
  fiscal years beginning after November 15, 2007, and interim periods within those
  fiscal years. Earlier application is encouraged, provided that the reporting
  entity has not yet issued financial statements for that fiscal year, including
  any financial statements for an interim period within that fiscal year.

The Company does not expect that the
  adoption of these new accounting pronouncements will have a significant effect
  on its financial statements.

(t) Reclassifications

Certain amounts reported in the prior
  periods have been reclassified to conform to the current periods presentation.

F-10

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|3. | DEFERRED ACQUSITION COSTS
|-- | -------------------------

On November 28, 2006, Vitavea entered
  into an agreement to acquire 100% of the issued and outstanding shares of two
  companies, Adolf Baur GmbH (Baur) and MEBA Medizinische Badebetriebsgesellschaft
  mbH (MEBA) for an aggregate purchase price of Euro 2,250,000 (approximately
  US -$3,070,845) of which a total of Euro 950,000 (US -$1,296,579) has already
  been paid. Baur and MEBA are companies engaged in the business of manufacturing
  and distributing medicinal mineral bath products. The remaining amount of the
  purchase price, with interest payable thereon, is due as follows:

| | (i)   | Euro 250,000 plus interest accrued at a rate of 6% per
        annum beginning on December 10, 2006, on or before March 1, 2007                 
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------
| |       |                                                                                                                                                 
| | (ii)  | Euro 250,000 plus interest accrued at a rate of 6% per
        annum beginning on December 10, 2006, on or before June 1, 2007                  
| |       |                                                                                                                                                 
| | (iii) | Euro 250,000 plus interest accrued at a rate of 6% per
        annum beginning on December 10, 2006, on or before September 1, 2007;
        and
| |       |                                                                                                                                                 
| | (iv)  | Euro 550,000 plus interest accrued at a rate of 6% per
        annum beginning on December 10, 2006, on or before December 1, 2007              

Upon closing, the total amount of the
  purchase price will be adjusted based on the total receivables and liabilities
  of Baur and MEBA, with the amount of the purchase price increasing if BAUR and
  MEBA have net receivables as compared to liabilities on December 1, 2007 and
  the amount of the purchase price decreasing if BAUR and MEBA have net liabilities
  as compared to receivables on that date.

In April 2007, the principals of Baur
  and MEBA notified Vitavea that they were terminating the agreement due to non-payment.
  Vitavea withheld the March and June 2007 ((i) and (ii) above) instalments as
  the principals of Baur and MEBA had failed to provide full and open disclosure
  regarding the operations and financial results of those companies on an ongoing
  basis as required under the agreement. The Company is currently negotiating
  with the principals of Baur and MEBA to reinstate the agreement and/or recover
  the purchase price already paid. The Company has recorded a writedown of the
  purchase price paid as substantial doubt exists.

|4. | EQUIPMENT AND PATENTS
|-- | ---------------------

Equipment

| |                          |   |           |  
| | ------------------------ | - | --------- | -
| |                          |   | April 30, |  
| |                          |   | 2007      |  
| |                          |   |           |  
| | Computer equipment       |   | 3,217     |  
| | Accumulated depreciation |   | (1,426    | )
| |                          |   |           |  
| | Net book value           | $ | 1,791     |  

F-11

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|4. | EQUIPMENT AND PATENTS (continued)
|-- | ---------------------------------

Patent

| |                          |   |           |  
| | ------------------------ | - | --------- | -
| |                          |   | April 30, |  
| |                          |   | 2007      |  
| |                          |   |           |  
| | Patent                   | $ | 28,534    |  
| | Accumulated depreciation |   | (2,942    | )
| |                          |   |           |  
| | Net book value           | $ | 25,592    |  

In the event that facts and circumstances
  indicate that the carrying amount of an asset may not be recoverable and an
  estimate of future undiscounted cash flows is less than the carrying amount
  of the asset, an impairment loss will be recognized. Management's estimates
  of revenues, operating expenses, and operating capital are subject to certain
  risks and uncertainties which may affect the recoverability of the Company's
  investments in its assets. Although management has made its best estimate of
  these factors based on current conditions, it is possible that changes could
  occur which could adversely affect management's estimate of the net cash flow
  expected to be generated from its operations.

|5. | LOANS PAYABLE - CURRENT
|-- | -----------------------

During the six months ended April 30,
  2007, several loans were granted from a third party individual totaling Euro
  238,000 (US -$324,827) of which Euro 125,000 (US -$170,602) was repaid in the
  same period. The loans are non-interest bearing and have no specific terms of
  repayment.

During the six months ended April 30,
  2007, a loan was granted from a third party individual totaling Euro 20,000
  (US -27,296). The loan is non-interest bearing and has no specific terms of
  repayment.

During the year ended October 31, 2006,
  a loan was granted from a third party company for $75,000. The loan bears interest
  at 8% per annum, compounded annually, and was due November 16, 2006. During
  the six months ended April 30, 2007, the third party company agreed to extend
  the term of the loan until November 17, 2007. Interest expense accrued for the
  six months ended April 30, 2007 totaled $2,778.

F-12

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|6. | RELATED PARTY TRANSACTIONS
|-- | --------------------------

Loans Payable Current

During the year ended October 31, 2006,
  a loan was granted from a director and officer of the Company and managing director
  of Vitavea for Euro 13,000 (US -$17,743) which was repaid in the six months
  ended April 30, 2007. During the six months ended April 30, 2007, a second loan
  was granted for Euro 48,000 (US -$65,511) of which Euro 33,000 (US -$45,039
  ) was repaid in the same period. The loans are non-interest bearing and have
  no specific terms for repayment.

Other

At April 30, 2007, included in accounts
  payable and accrued liabilities –related parties is Euro 4,700 (US -$6,415)
  owed to a company with a common managing director of the Company for office
  rent. Office rent expense for the six months ended April 30, 2007 totaled Euro
  12,000 (US -$15,711).

At April 30, 2007, included in accounts
  payable and accrued liabilities –related parties is Euro 1,000 (US -$1,365)
  owed to a managing director of Vitavea for management fees.

Management and consulting fees paid to
  officers and directors of the Company and the managing director of Vitavea for
  the six and three months ended April 30, 2007 totaled $13,885 and $6,980. Amounts
  due to and from officers and directors are unsecured, non-interest bearing and
  due on demand.

|7. | COMMON STOCK
|-- | ------------

The Companys articles of incorporation
  allow it to issue up to 750,000,000 shares of common stock, par value $0.001.
  Effective January 17, 2006, the Company effected a stock split of its common
  stock by issuing ten new shares for each old share. Except as otherwise stated
  to the contrary in these financial statements, all references to shares and
  prices per shares have been adjusted to give retroactive effect to the stock
  split.

On March 31, 2004, the Company issued
  74,775,308 shares of common stock for total proceeds of Euro 50,000 (US -$68,350).

On November 13, 2006, the Company acquired
  all the issued and outstanding stock of Vitavea, which was accounted for as
  a recapitalization of the Company (Note 1) in exchange for 34,350,000 shares
  of common stock. The issued number of shares of common stock is that of the
  Company with adjustments made for differences in par value between the Company
  and Vitavea AG.

On December 11, 2006, the Company issued
  500,000 common shares at a price of Euro 1.00 (US -$1.33) per share for total
  proceeds of Euro 500,000 (US -$664,717) in a private placement transaction.

On December 29, 2006, the Company issued
  400,000 common shares at a price of Euro 1.00 (US -$1.31) per share for total
  proceeds of Euro 400,000 (US -$525,348) in a private placement transaction.

F-13

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|7. | COMMON STOCK (continued)
|-- | ------------------------

On February 5, 2007, the Company issued
  260,416 units at a price of Euro 0.96 (US -$1.24) per unit in a private placement
  transaction. Each unit consists of one share of the Companys common stock
  and one share purchase warrant for total proceeds of Euro 250,000 (US -$323,917).
  Each warrant entitles the holder to purchase an additional share of the Companys
  common stock at a price of Euro 0.96 (US -$1.24) per share for a period of one
  year from the date of closing.

On February 14, 2007, the Company issued
  150,000 units at a price of Euro 1.00 (US -$1.30) per unit in a private placement
  transaction. Each unit consists of one share of the Companys common stock
  and one share purchase warrant for total proceeds of Euro 150,000 (US -$194,856).
  Each warrant entitles the holder to purchase an additional share of the Companys
  common stock at a price of Euro 1.00 (US -$1.30) per share for a period of one
  year from the date of closing.

On March 12, 2007, the Company issued
  537,634 common shares at a price of Euro 0.93 (US -$1.22) per share for total
  proceeds of Euro 500,000 (US -$656,721) in a private placement transaction.

|8. | WARRANTS
|-- | --------

| | Date              | Issued  | Outstanding | Exercise Price             | Expiry Date      
| | ----------------- | ------- | ----------- | -------------------------- | -----------------
| |                   |         |             |                            |                  
| | February 5, 2007  | 260,416 | 260,416     | Euro 0.96 (US $1.24)       | February 5, 2008 
| | February 14, 2007 | 150,000 | 150,000     | Euro
      1.00 (US $1.30) | February 12, 2008

|9.  | SEGMENT INFORMATION                                                                                                                                                                                                                                                                                                                                      
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                          
|    | The Companys operations following the acquisition
        of Vitavea AG were conducted in one reportable segment, being the development
        of Vitaveas nutritional supplement business. The Companys
        equipment and patent are located in Germany.                                                                                        
|    |                                                                                                                                                                                                                                                                                                                                                          
|10. | COMMITMENTS                                                                                                                                                                                                                                                                                                                                              
|    |                                                                                                                                                                                                                                                                                                                                                          
|    | On August 1, 2005, Vitavea AG entered into a lease agreement
        with a company with a common managing director for tenancy of office space.
        The lease agreement requires monthly lease payments of Euro 2,000 (US
        -$2,730) plus taxes.                                                                                              
|    |                                                                                                                                                                                                                                                                                                                                                          
|    | On April 27, 2004, Vitavea entered into a vehicle lease
        agreement that expires on May 1, 2008. The vehicle lease agreement required
        an initial payment of Euro 4,900 (US -$6,688) plus taxes and requires
        monthly lease payments of Euro 276 (US -$377) plus taxes. The deposit
        will be refunded at the end of the lease.

F-14

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|April 30, 2007                                
|(Unaudited)                                   

|10. | SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH
      FLOWS
|--- | --------------------------------------------------------

| |                |   |              |  |   |            |  |   |            | 
| | -------------- | - | ------------ |  | - | ---------- |  | - | ---------- | 
| |                |   | Cumulative   |  |   |            |  |   |            | 
| |                |   | Amounts from |  |   |            |  |   |            | 
| |                |   | Inception    |  |   |            |  |   |            | 
| |                |   | (March 31,   |  |   | Six Months |  |   | Six Months | 
| |                |   | 2004) to     |  |   | Ended      |  |   | Ended      | 
| |                |   | April 30,    |  |   | April 30,  |  |   | March 31,  | 
| |                |   | 2007         |  |   | 2007       |  |   | 2006       | 
| |                |   |              |  |   |            |  |   |            | 
| | Cash paid for: |   |              |  |   |            |  |   |            | 
| | Interest       | $ | 5,036        |  | $ | -          |  | $ | -          | 
| | Income taxes   | $ | 6            |  | $ | -          |  | $ | 6          | 

Non-cash Transaction

Investing and financing activities that
  do not have an impact on current cash flows are excluded from the statement
  of cash flows.

During the period from inception (March
  31, 2004) to April 30, 2007, the Company issued 34,350,000 common shares for
  the acquisition of Vitavea AG.

During the period ended October 31, 2006,
  WKB agreed to waive its claim of Euro 1,578,000 (US -$2,029,655). A portion
  of the claim valued at Euro 974,767 (US -$1,240,459) was transferred into additional
  paid-in capital. The remaining portion, including accumulated interest totaling
  Euro 15,101 (US -$18,814) was recorded as a gain on settlement of debt in the
  amount of Euro 618,334 (US -$770,382).

F-15

---

|ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN
      OF OPERATION.
|------- | ----------------------------------------------------------------

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this Quarterly Report
constitute "forward-looking statements. These statements, identified by words
such as plan, "anticipate," "believe," "estimate," "should," "expect" and
similar expressions include our expectations and objectives regarding our future
financial position, operating results and business strategy. These statements
reflect the current views of management with respect to future events and are
subject to risks, uncertainties and other factors that may cause our actual
results, performance or achievements, or industry results, to be materially
different from those described in the forward-looking statements. Such risks and
uncertainties include those set forth under the caption "Management's Discussion
and Analysis or Plan of Operation" and elsewhere in this Quarterly Report. We
advise you to carefully review the reports and documents we file from time to
time with the United States Securities and Exchange Commission (the SEC),
particularly our Annual Reports on Form 10-KSB and our Current Reports on Form
8-K.

As used in this Quarterly Report, the terms "we, "us, "our,
the Company and Vitavea mean Vitavea Inc. and its subsidiaries, unless
otherwise indicated. All dollar amounts in this Quarterly Report are in U.S.
dollars unless otherwise indicated.

CORPORATE BACKGROUND

We were incorporated on March 10, 2004 under the laws of the
State of Nevada.

Effective November 13, 2006, we completed the acquisition of a
100% ownership interest of Vitavea AG. Prior to acquiring Vitavea, we had been
engaged in the business of producing, marketing and selling OpenOffice computer
software on CD-ROM. We produced CD-ROMs of OpenOffice software and marketed and
sold the discs via the Internet, through our website at www.gacompsi.com. Now
that we have acquired all of the outstanding shares of Vitavea, we have
discontinued our software business in order to focus our resources on developing
Vitaveas nutritional supplements business.

VITAVEA AG

Vitavea AG was formed on March 31, 2004 under the laws of the
Federal Republic of Germany. Vitavea AG is engaged in the business of marketing
and distributing nutritional supplements.

Currently, Vitavea AG is focusing on marketing three
nutritional supplements that it calls MENTAL VIT, MENTAL VIT Junior and Oliva
Vital.

In addition, Vitavea AG holds a patent for a chemical
composition that it hopes to be able to develop into an approved drug to be used
to assist in the maintenance of blood sugar levels. Vitavea AG hopes to begin
the drug approval process sometime in 2007.

Mental Vit and Mental Vit Junior

Vitavea AG has developed two nutritional supplements called
MENTAL VIT and MENTAL VIT Junior that it intends to sell in Germany.

3

---

Vitavea AG has developed MENTAL VIT and MENTAL VIT Junior to
provide a balanced combination of nutrients essential to a healthy body.
Vitamins, minerals and other trace elements play a vital role in maintaining a
healthy body. These substances are used by the body to convert food into energy,
to promote tissue and cell growth, to build and maintain the bodys immune
system, to produce vital hormones and enzymes, and to detoxify the body.
However, the human body is incapable of producing many of these vitamins,
minerals and trace elements on its own. In addition, although the variety of
foods available for consumption is greater than ever before, it is still
extremely difficult for people to maintain the proper nutritional balance
through choice of foods alone. MENTAL VIT and MENTAL VIT Junior are designed to
bridge this gap.

MENTAL VIT is a nutritional supplement containing 26 important
vitamins, minerals and trace elements, designed to meet a bodys needs. In
addition, MENTAL VIT provides a full daily dosage of important anti-oxidants and
carotenoids. MENTAL VIT is designed to deliver the body with key nutrients
essential to a healthy body. In addition, MENTAL VITs combination of key
nutrients can counteract the ageing process and increase mental and physical
functioning.

MENTAL VIT Junior is a special formulation designed by Vitavea
AG specifically for children and teenagers under the age of 16.

Oliva Vital

Oliva Vital is a nutritional supplement based upon oleuropein,
an olive oil extract found in the bark, roots, leaves and fruit of the olive
tree. This natural substance helps to make the olive tree resistant against
parasites and diseases. When ingested, oleuropein can act as a boost to the
bodys immune system, strengthening its ability to resist viruses and bacteria.
In addition, oleuropein can have an important antioxidant effect, shielding the
body against the damage caused by free radicals. Oliva Vital also contains
L-Carnitine, a substance that can assist the fat-burning process and help
promote the circulation of blood through the heart.

RECENT CORPORATE DEVELOPMENTS

The following significant developments have occurred since the
completion of our January 31, 2007 fiscal quarter:

|1. | 1. On February 5, 2007, we completed a private
        placement for 260,416 units at a price of EUR 0.96 (approximately $1.24)
        per unit, for total proceeds of approximately EUR 250,000 (approximately
        $323,917). Each unit consists of one share of our common stock and one
        share purchase warrant, with each share purchase warrant entitling the
        holder to purchase one additional share of our common stock at a price
        of EUR 0.96 per share for a period of one year from the date the warrant
        was issued. The subscribed for shares were sold in reliance on the provisions
        of Regulation S under the Securities Act on the basis that each subscriber
        was not a US person as defined in Regulation S. No underwriting discounts
        or commissions were involved.
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|2. | 2. On February 14, 2007, we completed a private placement
        for 150,000 units at a price of EUR 1.00 (approximately $1.30) per unit,
        for total proceeds of approximately EUR 150,000 (approximately $194,856).
        Each unit consists of one share of our common stock and one share purchase
        warrant, with each share purchase warrant entitling the holder to purchase
        one additional share of our common stock at a price of EUR 1.00 per share
        for a period of                                                                                                                                                                                                                                                                                                                                   

4

---

|   | one year from the date the warrant was issued. The
      subscribed for shares were sold in reliance on the provisions of
      Regulation S under the Securities Act on the basis that each subscriber
      was not a US person as defined in Regulation S. No underwriting discounts
      or commissions were involved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|3. | 3. On March 12, 2007, we completed a private placement
        for 537,634 shares of our common stock at a price of EUR 0.93 (approximately
        $1.22) per share, for total proceeds of EUR 500,000 (approximately $656,721).
        The subscribed for shares were sold in reliance on provisions of Regulation
        S under the Securities Act of 1933 (the “Securities Act”)
        on the basis that the sole subscriber was not a US person as defined in
        Regulation S. No underwriting discounts or commissions were involved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|4. | 4. In April, 2007, the principals of Adolf Baur GmbH
        (“Baur”) and MEBA Medizinische Badebetriebsgesellschaft mbH
        (“MEBA”) notified us that they were terminating our agreement
        to purchase those companies. Under the terms of the agreement, we had
        agreed to acquire Baur and MEBA for an aggregate purchase price of EUR
        2,250,000 (approximately $3,070,845), of which EUR 950,000 (approximately
        $1,296,579) has already been paid. The agreement called for the remaining
        amount of the purchase price to be paid in installments. The first of
        these payments was to be made on March 1, 2007, with a second payment
        due on June 1, 2007. (See “Plan of Operation,” below.) We
        had withheld payment of the March and June installments as the principals
        of Baur and MEBA had failed to provide us with full and open disclosure
        regarding the operations and financial results of those companies on an
        ongoing basis as required under the agreement. We are currently negotiating
        with the principals of Baur and MEBA in an effort to reinstate our agreement.
        Although our management still hopes to be able to complete the acquisition
        of these companies, there is a substantial doubt that we will be able
        to do so. If we are not able to complete the acquisition of Baur and MEBA,
        we will seek to recover the portion of the purchase price already paid
        by us. However, there are no assurances that we will be able to do so.

PLAN OF OPERATION

Our plan of operation for the next twelve months will involve
the following:

|(a) | Product Marketing Efforts: During the next twelve
      months, Vitavea AG will attempt to develop the market for its MENTAL VIT,
      MENTAL VIT Junior and Oliva Vital product lines. Vitavea AG will focus on
      marketing its products to local pharmacies and drug stores in Germany. In
      addition, Vitavea AG intends to launch a television advertising campaign
      on local television stations and a printed media campaign appearing in
      local magazines. Finally, Vitavea AG will explore the feasibility of
      direct marketing campaigns to be directed at German health and wellness
      centers.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|(b) | Product Development Efforts: Vitavea AG will begin
      product development efforts in order to expand its current product lines.
      Currently, Vitavea AG plans to work on developing a skin cream to be used
      for smoothing the skin and on developing a usable drug for maintaining
      blood sugar levels based on its chromium formulation. In addition, Vitavea
      AG is exploring the possibility of developing medical bath
  products.                                                                                                                                                                        

We anticipate that we will require approximately EUR 5,300,000
(approximately $7,238,500) over the next twelve months in order to complete
Vitavea AGs plan of operation. This amount will be

5

---

spent on marketing and advertising efforts, product development
efforts and on general administrative expenses related to the operation of our
business.

In November, 2007, we entered into an agreement to acquire Baur
  and MEBA, two companies engaged in the business of manufacturing and distributing
  medicinal mineral bath products. Under the terms of our agreement, the aggregate
  purchase price for Baur and MEBA is EUR 2,250,000 (approximately $3,070,845),
  of which EUR 950,000 (approximately $1,296,579) has already been paid. The agreement
  calls for the remaining amount of the purchase price to be paid as follows:

| | (i)   | EUR 250,000 (approximately $341,500) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before March 1, 2007;        
| | ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | (ii)  | EUR 250,000 (approximately $341,500) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before June 1, 2007;         
| | (iii) | EUR 250,000 (approximately $341,500) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before September 1, 2007; and
| | (iv)  | EUR 550,000 (approximately $751,000) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before December 1, 2007.     

As discussed above, we had withheld the March 1, 2007 and June
1, 2007 payments because the principals of Baur and MEBA have failed to provide
us with full and open disclosure regarding the ongoing operations and financial
results of those companies as required under the terms of our agreement. In
April, 2007, the principals of Baur and MEBA notified us that they were
terminating the provisions of our agreement. We are currently negotiating with
the principals of Baur and MEBA in an effort to reinstate our agreement.
Although our management still hopes to be able to complete the acquisition of
these companies, there is a substantial doubt that we will be able to do so. If
we are not able to complete the acquisition of Baur and MEBA, we will seek to
recover the portion of the purchase price already paid by us. However, there are
no assurances that we will be able to do so.

RESULTS OF OPERATIONS

Under generally accepted accounting principles, the acquisition
of Vitavea AG has been accounted for as a reverse takeover of Vitavea and
Vitavea AG has been treated as the acquiring entity for accounting and financial
reporting purposes. As such, our consolidated financial statements are presented
as a continuation of the operations of Vitavea AG and not Vitavea. The financial
information provided below for the period ended March 31, 2006 represents the
operations of Vitavea AG. The operations of Vitavea are included from the
effective date of the acquisition, November 13, 2006.

Vitavea AG changed its year-end from December 31 to October 31
prior to completion of the acquisition. As a result, comparative information to
the six months ended March 31, 2006 has been included in this Quarterly Report.

Second Quarter and Six Months Summary

| |  |                |  |  | Three Months |  |  |            |  |  |                |  |  | Six Months |  |  |            | 
| |  | -------------- |  |  | ------------ |  |  | ---------- |  |  | -------------- |  |  | ---------- |  |  | ---------- | 
| |  | Three Months   |  |  | Ended        |  |  | Percentage |  |  | Six Months     |  |  | Ended      |  |  | Percentage | 
| |  | Ended          |  |  | March 31,    |  |  | Increase / |  |  | Ended          |  |  | March 31,  |  |  | Increase / | 
| |  | April 30, 2007 |  |  | 2006         |  |  | (Decrease) |  |  | April 30, 2007 |  |  | 2006       |  |  | (Decrease) | 

6

---

|Revenue             | $ | 2,011      |   | $ | 225      |   |  | 793.8% |    | $ | 15,903     |   | $ | 798        |   |  | 1892.9%  
|------------------- | - | ---------- | - | - | -------- | - |  | ------ | -- | - | ---------- | - | - | ---------- | - |  | ---------
|Costs of Goods Sold |   | (277       | ) |   | (277     | ) |  | n/a    |    |   | (1,564     | ) |   | (19,341    | ) |  | (91.9 )% 
|Expenses            |   | (127,252   | ) |   | (858,153 | ) |  | (85.2  | )% |   | (1,247,219 | ) |   | (1,389,719 | ) |  | (10.3 )% 
|Interest Income     |   | --         |   |   | 15,698   |   |  | (100.0 | )% |   | --         |   |   | 29,844     |   |  | (100.0 )%
|Interest Expense    |   | (1,463     | ) |   | --       |   |  | n/a    |    |   | (2,778     | ) |   | (18,798    | ) |  | (85.2 )% 
|Writedown of        |   | (1,260,381 | ) |   | --       |   |  | n/a    |    |   | (1,260,381 | ) |   | --         |   |  | n/a      
|Acquisition Costs   |   |            |   |   |          |   |  |        |    |   |            |   |   |            |   |  |          
|Loss Before Income  | $ | (1,387,362 | ) | $ | (842,507 | ) |  | 64.7%  |    | $ | (2,496,039 | ) | $ | (1,397,216 | ) |  | 78.6%    
|Taxes               |   |            |   |   |          |   |  |        |    |   |            |   |   |            |   |  |          

Revenue

We have only earned nominal revenues to date. We are still in
the process of developing our business and there are no assurances that we will
earn significant revenues in the future.

Operating Expenses

Our expenses for the quarterly period ended April 30, 2007 and
the quarterly period ended March 31, 2006 consisted of the following:

|                         |   | Three     |   |   | Three     |  |  |            |    |   |            |   |   |            |  |  |           
|------------------------ | - | --------- | - | - | --------- |  |  | ---------- | -- | - | ---------- | - | - | ---------- |  |  | ----------
|                         |   | Months    |   |   | Months    |  |  |            |    |   | Six Months |   |   | Six Months |  |  |           
|                         |   | Ended     |   |   | Ended     |  |  | Percentage |    |   | Ended      |   |   | Ended      |  |  | Percentage
|                         |   | April 30, |   |   | March 31, |  |  | Increase / |    |   | April 30,  |   |   | March 31,  |  |  | Increase /
|                         |   | 2007      |   |   | 2006      |  |  | (Decrease) |    |   | 2007       |   |   | 2006       |  |  | (Decrease)
|Amortization             | $ | 1,306     |   | $ | 253       |  |  | 416.2%     |    | $ | 2,588      |   | $ | 2,767      |  |  | (6.5 )%   
|Professional fees        |   | 180,912   |   |   | 1,956     |  |  | 9,149.1%   |    |   | 290,795    |   |   | 29,709     |  |  | 878.8%    
|Management fees          |   | 6,981     |   |   | 3,738     |  |  | 86.8%      |    |   | 13,886     |   |   | 7,473      |  |  | 85.8%     
|Marketing expenses       |   | (98,690   | ) |   | 830,668   |  |  | (111.9     | )% |   | 667,656    |   |   | 1,158,279  |  |  | (42.4 )%  
|Other operating expenses |   | 163,215   |   |   | 21,538    |  |  | 657.8%     |    |   | 376,948    |   |   | 191,491    |  |  | 96.8%     
|Foreign currency gain    |   | (126,472  | ) |   | --        |  |  | n/a        |    |   | (104,654   | ) |   | --         |  |  | n/a       
|TOTAL                    | $ | 127,252   |   | $ | 858,153   |  |  | (85.2      | )% | $ | 1,247,219  |   | $ | 1,389,719  |  |  | (10.3 )%  

Additional professional fees for the period ended April 30,
2007 include legal, accounting and consulting fees incurred in connection with
our acquisition of Vitavea AG, the proposed acquisition of Baur and MEBA, and
meeting our ongoing reporting obligations under the Securities Exchange Act of
1934, as well as legal and accounting fees incurred in connection with our
ongoing business activities.

During the three months ended April 30, 2007, we cancelled a
television marketing contract, resulting in a net marketing expense recovery of
$98,690. Our business development plan relies heavily upon marketing and
promotional campaigns that we intend to carry out. As a result, we expect that
we will continue to spend large amounts on marketing expenses during the next 12
months.

Other operating expenses are primarily made up of amounts spent
on wages.

7

---

Writedown of Acquisition Costs

During the three months ended April 30, 2007, we wrote down the
amount of the deferred acquisition costs relating to the portion of the purchase
price for Baur and MEBA previously paid by us as a result of the termination of
our agreement to purchase those companies by the principals thereof. These
amounts represent amounts paid under the terms of our agreement to acquire those
companies. Although we are negotiating with the principals of Baur and MEBA in
an effort to reinstate our agreement, there is a substantial doubt that we will
be able to complete the acquisition of these companies. If we are unable to
complete the acquisition of Baur and MEBA, we will attempt to recover the
portion of the purchase price already paid by us. However, there is a
substantial doubt that we will be able to recover any of the amounts already
paid under this agreement. We are currently in discussions with the principals
for Baur and MEBA to resolve this issue.

LIQUIDITY AND CAPITAL RESOURCES

|Working Capital         |   |                   |   |   |                     |   |  |                       | 
|----------------------- | - | ----------------- | - | - | ------------------- | - |  | --------------------- | 
|                        |   |                   |   |   |                     |   |  | Percentage            | 
|                        |   | At April 30, 2007 |   |   | At October 31, 2006 |   |  | Increase / (Decrease) | 
|Current Assets          | $ | 980,043           |   | $ | 34,094              |   |  | 2,774.5%              | 
|Current Liabilities     |   | (655,976          | ) |   | (104,472            | ) |  | 527.9%                | 
|Working Capital Surplus | $ | 324,067           |   | $ | (70,378             | ) |  | 560.5%                | 
|(Deficit)               |   |                   |   |   |                     |   |  |                       | 

|Cash Flows                                                |   |                  |   |   |                  |  
|--------------------------------------------------------- | - | ---------------- | - | - | ---------------- | -
|                                                          |   | Six Months Ended |   |   | Six Months Ended |  
|                                                          |   | April 30, 2007   |   |   | March 31, 2006   |  
|Cash Flows Used In Operating Activities                   | $ | (1,969,744       | ) | $ | (877,310         | )
|Cash Flows Used In Investing Activities                   |   | (394,177         | ) |   | (33,095          | )
|Cash Flows From Financing Activities                      |   | 2,582,921        |   |   | 1,187,056        |  
|Net Increase in Cash (net of foreign currency translation | $ | 137,863          |   | $ | 56,988           |  
|effects)                                                  |   |                  |   |   |                  |  

Currently, we do not have sufficient financial resources to
complete our plan of operation for the next twelve months. Although management
still hopes to be able to complete the proposed acquisition of Baur and MEBA,
there is a substantial doubt that we will be able to do so. However, even if we
are able to restore our agreement to acquire those companies, we do not
currently have sufficient capital resources to pay the remaining purchase price.
We have not earned any significant revenues to date, and there are no assurances
that we will be able to generate significant revenues in the future. As such,
our ability to complete our plan of operation, and the proposed acquisition of
Baur and MEBA, is expected to be dependent upon our ability to obtain
substantial financing in the near term. To date, we have financed our operations
through sales of our equity securities and short-term loans. We have completed
the following financings since our fiscal quarter ended January 31, 2007:

|(a) | On February 5, 2007, we completed a private placement
        for 260,416 units at a price of EUR 0.96 (approximately $1.24) per unit,
        for total proceeds of approximately EUR 250,000
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

8

---

|    | (approximately $323,917). Each unit consists of one
        share of our common stock and one share purchase warrant, with each share
        purchase warrant entitling the holder to purchase one additional share
        of our common stock at a price of EUR 0.96 per share for a period of one
        year from the date the warrant was issued.                                                                                                                                                                                                
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|(b) | On February 14, 2007, we completed a private placement
        for 150,000 units at a price of EUR 1.00 (approximately $1.30) per unit,
        for total proceeds of approximately EUR 150,000 (approximately $194,856).
        Each unit consists of one share of our common stock and one share purchase
        warrant, with each share purchase warrant entitling the holder to purchase
        one additional share of our common stock at a price of EUR 1.00 per share
        for a period of one year from the date the warrant was issued.
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|(c) | On March 12, 2007, we completed a private placement
        for 537,634 shares of our common stock at a price of EUR 0.93 (approximately
        $1.22) per share, for total proceeds of EUR 500,000 (approximately $656,721).                                                                                                                                                                                                                                                                                                                          

We anticipate that we will continue to rely on equity sales of
our common shares in order to continue to fund our business operations. If we
are successful in completing any equity financings, of which there is no
assurance, our existing shareholders will experience a dilution of their
interest in our company. If we are not successful in raising sufficient
financing, we will not be able to complete our current plan of operation. We do
not have any specific alternatives to our current plan of operation and have not
planned for any such contingency. If we are not successful in raising sufficient
financing, our business may fail and our shareholders may lose all or part of
their investment.

OFF-BALANCE SHEET ARRANGEMENTS

We have no significant off-balance sheet arrangements that have
or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of
operations, liquidity, capital expenditures or capital resources that is
material to stockholders.

CRITICAL ACCOUNTING POLICIES

The financial statements presented with this Quarterly Report
on Form 10-QSB have been prepared in accordance with generally accepted
accounting principles in the United States of America for interim financial
information. These financial statements do not include all information and
footnote disclosures required for an annual set of financial statements prepared
under United States generally accepted accounting principles. In the opinion of
our management, all adjustments (consisting solely of normal recurring accruals)
considered necessary for a fair presentation of the financial position, results
of operations and cash flows as at April 30, 2007 and for all periods presented
in the attached financial statements, have been included. Interim results for
the six month period ended April 30, 2007 are not necessarily indicative of the
results that may be expected for the fiscal year as a whole.

Our significant accounting policies are described at Note 3 to
our financial statements for the six month period ended April 30, 2007.

9

---

RISKS AND UNCERTAINTIES

Need For Financing

We do not currently have the financial resources to complete
our plan of operation for the next twelve months. We anticipate that we will
require approximately $7,238,500 in financing in order to fund our plan of
operation over the next twelve months. In addition, if we are able to restore
our agreement to acquire Baur and MEBA, of which there are no assurances, we
will need least an additional $1,775,500 to fund the acquisition of those
companies. We presently do not have any financing arrangements in place and
there is no assurance that we will be able to obtain sufficient financing on
terms acceptable to us or at all. If further financing is not available or
obtainable, our ability to meet our financial obligations and pursue our plan of
operation will be substantially limited and investors may lose a substantial
portion or all of their investment.

There Is A Risk That We May Not Complete The Acquisition Of
Baur And MEBA

In April, 2007, we received notice from the principals of Baur
and MEBA that they were terminating our agreement to acquire these companies. We
are currently in negotiations with the principals of Baur and MEBA in an effort
to restore our agreement. However, although our management is hopeful that we
will still be able to complete the acquisition of Baur and MEBA, there is a
substantial doubt that we will be able to do so. Even if we are able to restore
our agreement to acquire Baur and MEBA, we do not currently have the capital
resources to pay the remainder of the purchase price and there are no assurances
that we will be able to obtain sufficient financing to allow us to make the
required payments.

If we are not able to complete the acquisition of these
companies, we will attempt to recover the portion of the purchase price already
paid by us. However, there are no assurances that we will be able to do so.

Limited Operating History, Risks Of A New Business
Venture

Vitavea AG was formed on March 31, 2004 and, as such, has a
very short operating history upon which future performance may be assessed.
Vitavea AG has only earned nominal revenues to date.

Potential investors should be aware of the difficulties
normally encountered by a new enterprise and the high rate of failure of such
enterprises. The potential for future success must be considered in light of the
problems, expenses, difficulties complications and delays encountered in
connection with the development of a business in the area in which we intend to
operate and in connection with the formation and commencement of operations of a
new business in general. These include, but are not limited to, unanticipated
problems relating to research and development programs, marketing, approvals by
government agencies, competition and additional costs and expenses that may
exceed current estimates. There is no history upon which to base any assumption
as to the likelihood that our business will prove successful, and there can be
no assurance that we will generate any operating revenues or ever achieve
profitable operations.

We May Become The Subject Of Product Liability Suits

We could become subject to product liability claims in
connection with the use of our nutritional supplements or any other future
products that we develop. If we do become the subject of such

10

---

claims, we may not have sufficient financial resources to
defend against such claims or to satisfy any judgments made against us. We do
not currently carry product liability insurance and there are no assurances that
we will carry such insurance in the future. If we become the subject of such
claims and are unable to defend against such claims or are unsuccessful in
defending against such claims, our business may fail.

Nutritional Supplements Are Subject To Extensive Government
Regulation

The nutritional supplements industry is heavily regulated, and
  those regulations are changing at a rapid pace. Although Vitavea AG has obtained
  regulatory approval for its MENTAL VIT, MENTAL VIT Junior and Oliva Vital products
  within Germany, there are no assurances that it will not be required to obtain
  additional approvals in the future. In addition, if Vitavea AG is successful
  in developing its chromium formulation or any other products, of which there
  are no assurances, it will be required to obtain regulatory approval for those
  products prior to bringing them to market. In order to obtain approval for its
  products, Vitavea AG may be required to prove the effectiveness and safety of
  its products. In addition, Vitavea AG could be required to conduct lengthy and
  expensive clinical trials of its products. Obtaining regulatory approval for
  Vitavea AG’s products could be a lengthy and expensive process. There
  are no assurances that Vitavea AG will be able to meet the future costs of obtaining
  any necessary approvals or that Vitavea AG will be able to obtain such approvals
  at all.

The Nutritional Supplements Industry Is Highly Competitive.
Many Of Our Competitors Are Better Established And Have Greater Resources
Than We Do

The nutritional supplements industry is highly competitive.
Many of our competitors are better established and have substantially greater
capital resources, research and development capabilities, and personnel
resources than we do. These companies may be better able than us to develop,
refine and manufacture new products and may be better able to market their
existing products. In addition, many of these competitors have products and
brand names with a high degree of customer awareness and customer loyalty. If we
are not able to overcome the competitive advantages possessed by our
competition, our business may fail.

Dependence On Key Personnel

Our future success will largely depend upon the performance of
our directors and officers and the managers of Vitavea AG. Our success will also
depend upon our ability to attract and retain skilled technical, research,
management, sales and marketing personnel. Competition for such personnel is
intense. The loss of key personnel or the inability to attract and retain key
personnel could have a significantly detrimental effect on our business,
operating results and financial condition.

|ITEM 3. | CONTROLS AND PROCEDURES.
|------- | ------------------------

Under the supervision and with the participation of our
management, including our principal executive officer and principal financial
officer, we have evaluated the effectiveness of our disclosure controls and
procedures as required by Exchange Act Rule 13a-15(b) as of the end of the
period covered by this report. Based on that evaluation, our principal executive
officer and principal financial officer has concluded that these disclosure
controls and procedures are effective.

11

---

There were no changes in our internal control over financial
reporting during the last fiscal quarter that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.

12

---

PART II - OTHER INFORMATION

|ITEM 1. | LEGAL PROCEEDINGS.
|------- | ------------------

None.

|ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND
      USE OF PROCEEDS.
|------- | ------------------------------------------------------------------

None.

|ITEM 3. | DEFAULTS UPON SENIOR SECURITIES.
|------- | --------------------------------

None.

|ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY
      HOLDERS.
|------- | ----------------------------------------------------------

None.

|ITEM 5. | OTHER INFORMATION.
|------- | ------------------

Termination of a Material Agreement.

In April, 2007, we received notice from the principals of Adolf
Baur GmbH (Baur) and MEBA Medizinische Badebetriebsgesellschaft mbH (MEBA)
that they were terminating our agreement to purchase those companies. (See Part
I, Item 2, Managements Discussion and Analysis or Plan of Operation.) We are
currently in discussions with the principals of Baur and MEBA to reinstate our
agreement. Although our management still hopes to be able to complete the
acquisition of these companies, there is a substantial doubt that we will be
able to do so.

If we are not able to complete the acquisition of Baur and
MEBA, we will seek to recover the portion of the purchase price already paid by
us. However, there are no assurances that we will be able to do so.

Unregistered Sales of Equity Securities.

Since the end of our January 31, 2007 fiscal quarter, we have
completed three private placement financings:

|(a) | a private placement financing completed on February 5,
      2007 for approximately $341,437;     
|--- | --------------------------------------------------------------------------------------------------
|    |                                                                                                   
|(b) | a private placement financing completed on February 14,
      2007 for approximately $204,863; and
|    |                                                                                                   
|(c) | a private placement financing completed on March 12, 2007
      for approximately $537,634.       

A description of these private placement financings is included
in this Quarterly Report at Part I, Item 2., Managements Discussion and
Analysis or Plan of Operation.

13

---

|ITEM 6. | EXHIBITS.
|------- | ---------

|Exhibit |                                                                                                                                                                                                                                                  
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Number  | Description of Exhibits                                                                                                                                                                                                                          
|3.1     | Articles of Incorporation.(1)                                                                                                                                                                                                                    
|3.2     | Amendment to Articles of Incorporation
        filed March 14, 2005.(1)                                                                                                                                                                          
|3.3     | Certificate of
        Change to Authorized Capital effective January 17, 2006.(2)                                                                                                                                                               
|3.4     | Certificate of Amendment to Articles
        of Incorporation  name change to Vitavea Inc. effective
        November 27, 2006.(8)                                                                                                            
|3.5     | Bylaws.(1)                                                                                                                                                                                                                                       
|10.1    | GNU General Public License (GPL).(1)                                                                                                                                                                                                             
|10.2    | GNU Lesser General
        Public License (LGPL).(1)                                                                                                                                                                                             
|10.3    | Sun Industry Standards Source
        License (SISSL).(1)                                                                                                                                                                                        
|10.4    | Loan Agreement
        with Blackpointe Holdings Inc.(3)                                                                                                                                                                                         
|10.5    | Share Purchase Agreement among
        the Company, Vitavea AG, WKB Beteiligungsgesellschaft mbH, Crystalwood
        Holdings Ltd., Peter J. Hoyle and Lina Zhou, dated for reference the 31stday of July, 2006.(4)                             
|10.6    | Extension Letter
        from WKB Beteiligungsgesellshaft mbH dated August 23, 2006.(5)                                                                                                                                                          
|10.7    | Loan Agreement between the Company
        and Vitavea AG dated as of August 31, 2006.(5)                                                                                                                                                        
|10.8    | Promissory Note
        executed by Vitavea AG as of August 31, 2006.(5)                                                                                                                                                                         
|10.9    | Extension Letter from WKB Beteiligungsgesellshaft
        mbH dated September 15, 2006.(6)                                                                                                                                                       
|10.10   | Loan Agreement
        between the Company and Vitavea AG dated as of October 3, 2006.(7)                                                                                                                                                        
|10.11   | Promissory Note executed by Vitavea
        AG as of October 3, 2006.(7)                                                                                                                                                                         
|10.12   | Loan Agreement
        between the Company and Vitavea AG dated as of October 11, 2006.(7)                                                                                                                                                       
|10.13   | Promissory Note executed by Vitavea
        AG as of October 11, 2006.(7)                                                                                                                                                                        
|10.14   | Amendment Agreement
        to the Loan Agreement between the Company and Black Pointe Holdings Inc.,
        dated for reference the 16thday of November, 2006.(8)                                                                              
|10.15   | Purchase Agreement between Vitavea
        AG, Carmen Otho-Loefert, Meba Medizinische Badebetriebsgesellschaft MBH
        and Adolf Baur GmbH, dated for reference the 28thday of November,
        2006 (translated from German to English).(8)
|14.1    | Code of Ethics.(1)                                                                                                                                                                                                                               
|31.1    | Certification
        of Chief Executive Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.                                                                                                                   
|31.2    | Certification
        of Chief Financial Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.                                                                                                                   
|32.1    | Certification
        of Chief Executive Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.                                                                                                                   
|32.2    | Certification
        of Chief Financial Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.                                                                                                                   

|(1) | Filed with the SEC as an exhibit to our Registration
      Statement on Form SB-2 originally filed on May 4, 2005, as
  amended.
|--- | --------------------------------------------------------------------------------------------------------------------------------
|(2) | Filed with the SEC as an exhibit to our Current Report on
      Form 8-K filed on January 17, 2006.                             
|(3) | Filed with the SEC as an exhibit to our Quarterly Report
      on Form 10-QSB filed on June 14, 2006.                           
|(4) | Filed with the SEC as an exhibit to our Current Report on
      Form 8-K filed on August 9, 2006.                               

14

---

|(5) | Filed with the SEC as an exhibit to our Current Report on
      Form 8-K filed on September 5, 2006.  
|--- | ------------------------------------------------------------------------------------------------------
|(6) | Filed with the SEC as an exhibit to our Current Report on
      Form 8-K filed on September 21, 2006. 
|(7) | Filed with the SEC as an exhibit to our Current Report on
      Form 8-K filed on October 19, 2006.   
|(8) | Filed with the SEC as an exhibit to our Annual Report on
      Form 10-KSB filed on February 13, 2007.

15

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|      |               |  |     | VITAVEA INC.                                    
|----- | ------------- |  | --- | ------------------------------------------------
|      |               |  |     |                                                 
|      |               |  |     |                                                 
|Date: | June 19, 2007 |  | By: | /s/
      Roger Liere                           
|      |               |  |     | ROGER LIERE                                     
|      |               |  |     | Chief Executive Officer and President           
|      |               |  |     | (Principal Executive Officer )                  
|      |               |  |     |                                                 
|      |               |  |     |                                                 
|      |               |  |     |                                                 
|      |               |  |     |                                                 
|Date: | June 19, 2007 |  | By: | /s/
      John Boschert                         
|      |               |  |     | JOHN BOSCHERT                                   
|      |               |  |     | Chief Financial Officer, Secretary and Treasurer
|      |               |  |     | (Principal Accounting Officer)                  

---